<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Re-188-RC-160, a radiolabeled somatostatin analogue, is being explored for its potential as a local/regionally administered radiotherapeutic agent targeting somatostatin receptor-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In studies in vitro and in vivo, Re-188-RC-160 was found to bind to somatostatin receptor-positive cells (NCI-H69, human small cell <z:mp ids='MP_0008714'>lung carcinoma</z:mp>), but not to binding-negative cells (Raji, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) </plain></SENT>
<SENT sid="2" pm="."><plain>The comparative binding of Re-188-labeled RC-160 [cyclic <z:chebi fb="0" ids="29337,29340">NH2-</z:chebi>(D)-Phe-Cys-Try-(D)<z:chebi fb="0" ids="32708">-Trp</z:chebi>-Lys-Val-Cys<z:chebi fb="0" ids="32708">-Trp</z:chebi>-<z:chebi fb="0" ids="29318,29339">NH2</z:chebi>] or CTOP [cyclic <z:chebi fb="0" ids="29337,29340">NH2-</z:chebi>(D)-Phe-Cys-Try-(D)<z:chebi fb="0" ids="32708">-Trp</z:chebi><z:chebi fb="6" ids="44548">-Orn</z:chebi>-Thr-Pen-Thr-ol], a mu-opioid receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> used a negative control compound, was also determined in vitro and in vivo using NCI-H69 cells as targets </plain></SENT>
<SENT sid="3" pm="."><plain>Re-188-RC-160 demonstrated higher net binding in vitro and in vivo compared to Re-188-RC-CTOP, and in vitro its binding could be reduced by excess unlabeled RC-160 whereas binding of Re-188-CTOP could not be reduced </plain></SENT>
<SENT sid="4" pm="."><plain>Using another somatostatin receptor-positive human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> line, ZR-75-1, a substantial amount of the cell-bound Re-188-RC-160 was found to be internalized </plain></SENT>
<SENT sid="5" pm="."><plain>Does estimates for Re-188-RC-160 in animals containing NCI-H69 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> indicated that with three serial injections therapeutic doses greater than 60 Gy can be achieved </plain></SENT>
</text></document>